Business
Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that pre-clinical study results of IBI3011 (IL-1RAP monoclonal antibody) and IBI3034 (TACI/BCMA chimeric fusion protein) were showcased at American College of Rheumatology (ACR) Annual Meeting 2025. Details a
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that pre-clinical study results of IBI3011 (IL-1RAP monoclonal antibody) and IBI3034 (TACI/BCMA chimeric fusion protein) were showcased at American College of Rheumatology (ACR) Annual Meeting 2025. Details are listed below:","length":588,"tagName":"p"},{"type":"text","content":"Title: IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model (IBI3011)","length":194,"tagName":"p"},{"type":"text","content":"Abstract Number : 0082Presentation Form: PosterTime: October 26, 2025 10:30 AM – 12:30 PM (CT)Presenter: Dr. Hongling Tian","length":126,"tagName":"p"},{"type":"text","content":"IBI3011 is an innovative humanized monoclonal antibody blocking IL1α, IL1β, IL36 simultaneously, by targeting the extracellular domain of IL1RAP.","length":145,"tagName":"p"},{"type":"text","content":"It profoundly inhibits the activation of IL1α, IL1β, IL36 and effectively alleviates gout and arthritis in animals. It exhibits good pharmacokinetic properties and safety in monkeys. Furthermore, high concentration formulation has been developed to enable subcutaneous administration.","length":284,"tagName":"p"},{"type":"text","content":"To summarize, IBI3011 can be a best-in-class anti-IL1RAP differentiated from current therapies in depth of response and better convenience. The IND application of IBI3011 has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis.","length":278,"tagName":"p"},{"type":"text","content":"Title: Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease","length":210,"tagName":"p"},{"type":"text","content":"Abstract Number : 0906Presentation Form: PosterTime: October 27, 2025, 10:30 AM - 12:30 PM (CT)Presenter: Dr. Yao Xiong","length":122,"tagName":"p"},{"type":...